Further NeoLipa data to be presented at a key congress

Results from the ongoing NeoLipa study have been selected for oral presentation at the ESMO Immuno-Oncology and Advanced Therapies Congress 2026. We consider this an encouraging development, as the congress is a key specialist meeting and oral presentations are generally reserved for the most noteworthy abstracts. In our view, the selection highlights the significance of the data generated to date for ruxotemitide in the neoadjuvant melanoma setting.

What’s new? Lytix announced today that it will present results from the ongoing Phase II NeoLipa study at the ESMO Immuno-Oncology and Advanced Therapies Congress 2026, to be held in London on 14–16 December 2026.

What does it mean? The Phase II data has been selected for oral presentation as a late-breaking abstract in a Proffered Paper session at the congress. In our view, this is an encouraging signal, reflecting the scientific community’s interest in both ruxotemitide and the neoadjuvant melanoma setting. The selection also underscores the significance of the recently reported top-line data and may help increase awareness of the programme among key stakeholders. NeoLipa is an investigator-initiated study evaluating ruxotemitide in combination with Keytruda (pembrolizumab) as neoadjuvant treatment for patients with resectable melanoma.

What do we do? We look forward to gaining a deeper understanding of the NeoLipa study results at the congress and view this as a significant specialist event, providing Lytix with an opportunity to gain broader exposure among potential industry partners. We await the full data set before making any adjustments to our assumptions for ruxotemitide.